Apixaban Dosing Guidelines
Introduction to Apixaban Dosing
- The European Society of Cardiology recommends a standard dose of 5 mg orally twice a day for most patients with non-valvular atrial fibrillation, reduced to 2.5 mg twice a day if the patient meets at least 2 of 3 reduction criteria (age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) 1
Fibrilación Auricular No Valvular
- For non-valvular atrial fibrillation, the standard dose is 5 mg orally twice a day for most patients, according to the European Heart Journal 1
- The dose is reduced to 2.5 mg twice a day when the patient presents with at least 2 of the following 3 criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, as recommended by the European Heart Journal and Circulation 1, 2
Tratamiento de Tromboembolismo Venoso (TEV/EP)
- The initial treatment dose for venous thromboembolism is 10 mg orally twice a day for the first 7 days, followed by 5 mg twice a day, as stated in the European Heart Journal 1
- The maintenance dose after the first 7 days is 5 mg orally twice a day, continuing for at least 6 months, according to the European Heart Journal 1
Prevención de Recurrencia de TEV
- For the prevention of recurrent venous thromboembolism, the dose is 2.5 mg orally twice a day after completing at least 6 months of initial anticoagulant treatment, as recommended by the European Heart Journal 1
Cardioversión en Fibrilación Auricular
- For cardioversion with transesophageal echocardiography (TEE), at least one dose of apixaban ≥4 hours before the procedure is recommended by the European Heart Journal 1
- An alternative strategy is anticoagulation with apixaban for at least 3 weeks before cardioversion (without TEE), as stated in the European Heart Journal 1
Consideraciones Especiales de Seguridad
- The American College of Chest Physicians notes that apixaban has demonstrated a favorable bleeding profile compared to warfarina, with fewer major bleeding events 5
- In the treatment of pulmonary embolism, the incidence of major bleeding was significantly lower with apixaban (0.6% vs 1.8%; relative risk 0.31; P<0.001), according to Praxis Medical Insights 4